索拉非尼对原发性肝癌患者疗效的研究分析

Analysis of Sola Fini for Primary Liver Cancer

目的探讨索拉非尼对原发性肝癌患者的疗效,为原发性肝癌的治疗提供理论依据。方法选取103例采用索拉非尼治疗的原发性肝癌患者,检查末次随访时外周血淋巴细胞水平,并与治疗前进行对比,同时观察其疗效、不良反应及生存率情况。结果患者治疗后CD3+、CD4+、CD4+/CD8+及NK值显著上升,但CD8+水平显著下降,治疗前后比较存在显著差异;治疗前患者平均Karnofsky评分为(65.5±2.4)分,治疗后升至(79.8±5.2)分,患者治疗后生活质量显著高于治疗前;治疗后患者均出现不同程度的不良反应,以手足皮肤反应、口腔炎和腹泻最为明显,发生率分别为44.7%、40.8%及45.6%;随访6个月时共发现11例患者死亡,随访1年时共发现17例患者死亡,6个月、1年生存率分别为89.3%及83.5%。结论索拉非尼能够有效改善原发性肝癌患者机体免疫功能,延长其生存时间,且具有良好的安全性,可作为无法实施手术的原发性肝癌患者的首选治疗药物。

Objective To study the effect of Sola Fini on primary liver cancer ,and provide theoretical basis for the treat-ment of primary liver cancer .Methods 103 patients with primary liver cancer treated with Sola Fini were selected;peripheral blood lymphocyte levels was detected at the last follow-up,and compared with before treatment .Efficacy,adverse reactions and survival rates were observed .Results After treatment,CD3 ＋,CD4 ＋,CD4 ＋/CD8 ＋and NK increased significantly ,while CD8 ＋dropped significantly ,there were significant differences;the average Karnofsky score before and after treatment were （65.5 ±2.4） and （79.8 ±5.2 ）,quality of life of patients after treatment was significantly better than that before treatment ; the patients showed different degree of adverse reactions , with hand foot skin reaction , stomatitis and diarrhea as the most obvious , the oc-curence rates were 44.7%,40.8%and 45.6%,respectively;11 patients died during the 6-month follow-up,and 17 patients died during the 1-year of follow-up,6-month and 1-year survival rates were 89.3% and 83.5%,respectively.Conclusion Sola Fini can effectively improve immune function of primary liver cancer patients ,prolong the survival time ,and has a good safety ,it can be the first choice for primary liver cancer patients who can not receive operation .